PMID- 31870593
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20221207
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 216
IP  - 1
DP  - 2020 Jan
TI  - Link between CIITA rs3087456 polymorphism and the risk of laryngeal squamous cell 
      carcinoma in a Chinese population.
PG  - 152793
LID - S0344-0338(19)32019-9 [pii]
LID - 10.1016/j.prp.2019.152793 [doi]
AB  - The class II trans-activator (CIITA) is the master regulator of the major 
      histocompatibility complex (MHC) gene expression. CIITA mutations have been 
      previously associated with several kinds of tumors, while the role of CIITA 
      polymorphisms (rs3087456) in laryngeal squamous cell carcinoma (LSCC) is little 
      known. We evaluate the link between CIITA polymorphisms and the existence of LSCC 
      in patients. This study was conducted with 200 Chinese Han patients (LSCC) and 
      200 healthy control subjects. The association of CIITA genetic polymorphism 
      rs3087456 with the risk of LSCC was assessed through pyrosequencing. The CIITA 
      expression in LSCC tumor tissue and adjacent normal tissue was detected by 
      immunohistochemistry (IHC) staining. The relationship between the genotype of 
      rs3087456 in controls and in clinical pathology features in LSCC were analyzed, 
      and in-silico analysis was also used for the CIITA gene. The in-silico analysis 
      results showed that the CIITA gene is closely related to genes such as RFX5 and 
      RFXAP. The IHC results showed that CIITA was highly expressed in LSCC tumor 
      tissues, compared with the corresponding adjacent normal tissues. The AG, AG + 
      AA, and A genotypes of rs3087456 of CIITA gene notably increased the risk of LSCC 
      compared to the controls. Our study suggests that CIITA polymorphism (rs3087456) 
      is associated with a higher risk of developing LSCC in a Chinese cohort.
CI  - Copyright (c) 2019 Elsevier GmbH. All rights reserved.
FAU - Xue, Yi
AU  - Xue Y
AD  - Department of Otolaryngology, Eye Ear Nose & Throat Hospital, Fudan University, 
      Shanghai, PR China.
FAU - Tang, Di
AU  - Tang D
AD  - Department of Otolaryngology, Eye Ear Nose & Throat Hospital, Fudan University, 
      Shanghai, PR China.
FAU - Li, Sheng-Jie
AU  - Li SJ
AD  - Shanghai Key Clinical Disciplines of Otorhinolaryngology, Eye Ear Nose & Throat 
      Hospital, Fudan University, Shanghai, PR China.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Department of Otolaryngology, Eye Ear Nose & Throat Hospital, Fudan University, 
      Shanghai, PR China.
FAU - Hsueh, Chi-Yao
AU  - Hsueh CY
AD  - Department of Otolaryngology, Eye Ear Nose & Throat Hospital, Fudan University, 
      Shanghai, PR China.
FAU - Zhao, Dan-Dan
AU  - Zhao DD
AD  - Research Center, Shanghai Jiao Tong University Affiliated Chest Hospital, PR 
      China.
FAU - Heng, Yu
AU  - Heng Y
AD  - Department of Otolaryngology, Eye Ear Nose & Throat Hospital, Fudan University, 
      Shanghai, PR China.
FAU - Tao, Lei
AU  - Tao L
AD  - Department of Otolaryngology, Eye Ear Nose & Throat Hospital, Fudan University, 
      Shanghai, PR China. Electronic address: doctortaolei@163.com.
FAU - Lu, Li-Ming
AU  - Lu LM
AD  - Shanghai Institute of Immunology, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, PR China. Electronic address: lulunew2003@163.com.
LA  - eng
PT  - Journal Article
DEP - 20191218
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (MHC class II transactivator protein)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Trans-Activators)
SB  - IM
MH  - Adult
MH  - Asian People
MH  - Carcinoma, Squamous Cell/*genetics
MH  - Gene Frequency/genetics
MH  - Genetic Predisposition to Disease/*genetics
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nuclear Proteins/*genetics
MH  - Squamous Cell Carcinoma of Head and Neck/*genetics
MH  - Trans-Activators/*genetics
OTO - NOTNLM
OT  - CIITA
OT  - Laryngeal squamous cell carcinoma
OT  - Mutation
OT  - Polymorphism
OT  - SNP
EDAT- 2019/12/25 06:00
MHDA- 2020/11/25 06:00
CRDT- 2019/12/25 06:00
PHST- 2019/09/18 00:00 [received]
PHST- 2019/12/04 00:00 [revised]
PHST- 2019/12/12 00:00 [accepted]
PHST- 2019/12/25 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
PHST- 2019/12/25 06:00 [entrez]
AID - S0344-0338(19)32019-9 [pii]
AID - 10.1016/j.prp.2019.152793 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2020 Jan;216(1):152793. doi: 10.1016/j.prp.2019.152793. Epub 
      2019 Dec 18.